Your browser doesn't support javascript.
loading
Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection.
Nestler, Tim; Paffenholz, Pia; Pfister, David; Schoch, Justine; Nini, Alessandro; Hiester, Andreas; Albers, Peter; Heidenreich, Axel.
Afiliação
  • Nestler T; Department of Urology and Uro-Oncology, University Hospital of Cologne, Cologne, Germany.
  • Paffenholz P; Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany.
  • Pfister D; Department of Urology and Uro-Oncology, University Hospital of Cologne, Cologne, Germany.
  • Schoch J; Department of Urology and Uro-Oncology, University Hospital of Cologne, Cologne, Germany.
  • Nini A; Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany.
  • Hiester A; Department of Urology, Azienda ULSS 7 Pedemontana, Bassano del Grappa, Italy.
  • Albers P; Department of Urology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
  • Heidenreich A; Department of Urology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
J Urol ; 211(3): 426-435, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38085711
ABSTRACT

PURPOSE:

Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for advanced nonseminomatous germ cell tumors (GCTs) aims to resect all remaining metastatic tissue. Resection of adjacent visceral or vascular organs is commonly performed for complete resection. Resection of organs harboring only necrosis results in relevant overtreatment. The study aimed to describe the frequency of metastatic involvement of resected organs with teratoma or viable cancer and to analyze perioperative complications and relapse-free survival. MATERIALS AND

METHODS:

In a 2-center study, we reviewed a cohort of 1204 patients who underwent PC-RPLND between 2008 and 2021 and identified 242 (20%) cases of adjunctive surgery during PC-RPLND. We analyzed the removed adjacent structures and the pathohistological presence of GCT elements in the resected organs viable GCT, teratoma, or necrosis/fibrosis. Surgery-associated complications were reported according to the Clavien-Dindo classification.

RESULTS:

Viable GCT, teratoma, and necrosis were present in 54 (22%), 94 (39%), and 94 (39%), respectively, of all patients with adjunctive resection of adjacent organs. Vascular resections or reconstructions (n = 112; viable 23%, teratoma 41%, necrosis 36%) were performed most frequently, followed by nephrectomies (n = 77; viable 29%, teratoma 39%, necrosis 33%). Perioperative complications of grade ≥ IIIa occurred in 6.6% of all patients, with no difference between the viable GCT and teratoma/necrosis groups (P = .1). A total of 76 patients have been followed without a relapse for at least 36 months. Median follow-up of the whole cohort was 22 months (quartile 7 and 48). Patients with viable GCT/teratoma in the resected specimens had a significantly increased risk of recurrence by 5 years compared to patients with only necrosis (19% vs 59% vs 81%, P < .001).

CONCLUSIONS:

This study shows that 33% to 40% of all resections of adjacent organs do not harbor teratoma or viable GCT. This highlights the need for better patient selection for these complex patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Teratoma / Neoplasias Testiculares / Neoplasias Embrionárias de Células Germinativas Limite: Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Teratoma / Neoplasias Testiculares / Neoplasias Embrionárias de Células Germinativas Limite: Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article